Costimulation blockade - What will the future bring?

Nephrology Dialysis Transplantation

Volumn 22, Issue 5, 2007, Pages 1293-1296

  Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Belatacept; Costimulation blockade; Fusion receptor proteins

Indexed keywords

ABATACEPT; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CHI 220; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; EFALIZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANTIGEN BINDING; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEALTH CARE ACCESS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MEDICAL RESEARCH; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANIMALS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 34447542808     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl830     Document Type: Note

References (22)

1. Bluestone JA. CTLA-4Ig is finally making it: A personal perspective. Am J Transplant 2005; 5: 423-424
2. Vincenti F, Luggen M. T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 2007; 58: 23
3. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781
4. Lenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789-792
5. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453
6. Vincenti F. Protein therapies and antiproliferatives: A new paradigm in immunosuppression. Transplantation Rev 2005; 19: 179-185
7. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162: 2775-2784
8. Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51: 265-270
9. Lin H, Boiling SF, Linsley PS et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801-1806
10. Sayegh MH, Zheng XG, Magee C, Hancock WW, Turka AA. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 1997; 64: 1646-1650.
11. + T-cell-mediated allograft rejection. Am J Transplant 2005; 5: 31-39
12. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002; 13: 559-575
13. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-8794
14. Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-693
15. Kirk AD, Knechtle SJ, Sollinger HW, Vincenti F, Stecher S, Nadeau K. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001; 1: S191
16. Andre P, Prasad KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 257-252
17. Adams AB, Shirasugi N, Jones TR et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542-550
18. Vincenti F, Mendez R, Pescovitz M et al. A Phase I/II randomized open label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007 (in press)
19. Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+ CD25+ regulatory T cells. Novartis Found Symp 2003; 252: 106-114
20. Hirose K, Posselt AM, Stock PG, Hirose R, Vincenti F. Treatment of kidney transplant patients with the novel co-stimulatory blocker LEA29Y and anti-IL2 receptor antibody does not impede the development of regulatory T-cells. Am J Transplant 2004: 4[Suppl 8]: 442 (Abstract)
21. Belingheri M, Gross DM, Edefonti A, Bluestone JA, Vincenti F. Ratio of regulatory T cells to CD3 infiltrate predicts renal allograft outcome after acute cellular rejection. Presented at World Transplant Congress 2006; p. 635 (Abstract)
22. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342-2351